Bendamustine Glenmark 2,5 mg/ml Proszek do sporządzania koncentratu roztworu do infuzji Pólland - pólska - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

bendamustine glenmark 2,5 mg/ml proszek do sporządzania koncentratu roztworu do infuzji

glenmark pharmaceuticals s.r.o. - bendamustini hydrochloridum monohydricum - proszek do sporządzania koncentratu roztworu do infuzji - 2,5 mg/ml

Kymriah Evrópusambandið - pólska - EMA (European Medicines Agency)

kymriah

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - inne środki przeciwnowotworowe - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.